TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Free Report) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 18,600 shares, a decline of 53.5% from the March 31st total of 40,000 shares. Based on an average daily volume of 588,800 shares, […]
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. TransCode Therapeutics Stock Performance RNAZ stock opened at $0.50 on Tuesday. TransCode Therapeutics has a 52 week low of $0.47 and a 52 […]
TransCode Therapeutics (NASDAQ:RNAZ) Shares Down 2 9% etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 27,100 shares, an increase of 22.1% from the May 15th total of 22,200 shares. Currently, 4.4% of the shares of the stock are sold short. Based on […]
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) CEO Robert Michael Dudley bought 19,000 shares of the stock in a transaction on Friday, June 9th. The shares were acquired at an average cost of $2.76 per share, for a total transaction of $52,440.00. Following the acquisition, the chief executive officer now directly owns 912,114 shares in […]